Clinical trials
Cardiovascular Diseases trials in Czechia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
82 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 5 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 9 |
| 2013 | 4 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 6 |
| 2019 | 5 |
| 2021 | 1 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 8 |
| 2025 | 9 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 44 |
| Terminated | 10 |
| Active, not recruiting | 9 |
| Recruiting | 9 |
| Unknown status | 7 |
| Enrolling by invitation | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 9 |
| Abbott Medical Devices | 5 |
| Eli Lilly and Company | 5 |
| GlaxoSmithKline | 5 |
| AstraZeneca | 3 |
| Pfizer | 3 |
| Amgen | 2 |
| Boehringer Ingelheim | 2 |
| Boston Scientific Corporation | 2 |
| Cardurion Pharmaceuticals, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cardiovascular Diseases | 82 |
| Heart Diseases | 21 |
| Heart Failure | 18 |
| Diabetes Mellitus, Type 2 | 11 |
| Myocardial Infarction | 11 |
| Stroke | 11 |
| Atherosclerosis | 9 |
| Hypertension | 9 |
| Vascular Diseases | 7 |
| Coronary Artery Disease | 6 |
Trials
Showing 1 to 25 of 82. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.